Keytruda approved for second blood cancer
US regulators have again expanded the list of approved uses of MSD’s immunotherapy Keytruda, issuing a green light for the treatment of primary mediastinal large B-cell lymphoma (PMBCL).
Read More
Tag: PMBCL
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
